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Helicates and related metallofoldamers, synthesised by dynamic self-assembly, represent an area of
chemical space inaccessible by traditional organic synthesis, and yet with potential for discovery of new
classes of drug. Here we report that water-soluble, optically pure Fe(II)- and even Zn(II)-based triplex
metallohelices are an excellent platform for post-assembly click reactions. By these means, the in vitro
anticancer activity and most importantly the selectivity of a triplex metallohelix Fe(II) system are
dramatically improved. For one compound, a remarkable array of mechanistic and pharmacological
behaviours is discovered: inhibition of Na+/K+ ATPase with potency comparable to the drug ouabain,
antimetastatic properties (including inhibition of cell migration, re-adhesion and invasion), cancer stem
cell targeting, and ﬁnally colonosphere inhibition competitive with the drug salinomycin.Introduction
Lehn envisaged in the original report1 that helicates2–4 – self-
assembling multimetallic coordination compounds – may nd
uses in biochemistry. Indeed, while their underlying chemistry
is very diﬀerent to that of the small cationic a-helical peptide
units that are deployed in nature for e.g. signalling, structural
and host-defence roles,5–7 some such metallofoldamers8 have
similar dimensions and charge. With this in mind we have
developed several classes of water-compatible, optically pure
metallohelix compounds,9–11 each of which has unique proper-
ties, including a growing list of peptide-like behaviours: binding
of DNA motifs,12 anticancer activity,5,11,13 and the inhibition of
e.g. amyloid-b aggregation,12,14 enzyme activity15,16 and ice
recrystallization.17 Thus, while we cannot expressly mimic the
exquisite architectures of natural peptides, we are motivated to
seek methods by which diverse metallohelices might be rapidly
accessed and new biological properties discovered and
optimised.18arwick, Coventry CV4 7AL, UK. E-mail:
dderseld, Hudderseld, HD1 3DH, UK
Biophysics, Kralovopolska 135, CZ-61265
wick, Coventry CV4 7AL, UK
ESI) available: Data created during this
sity of Warwick Research Archive Portal
OI: 10.1039/c9sc02651g
Chemistry 2019The addition of new covalent bonds to supramolecular
assemblies by post-assembly modication (PAM) may be used
for various purposes including locking-down dynamic struc-
tures, triggering structural transformations, or simply late-stage
derivatisation to introduce new functional groups.19 The latter is
attractive to us since it may facilitate phenotypic discovery,
property optimisation or the elucidation of structure/activity
relationships, all without the need for extensive pre-assembly
ligand synthesis. Further, we may include functional groups
that are incompatible with the self-assembly. However, such
reactions must be clean and eﬃcient under mild conditions,
and we note that the lability or reactivity of many metal-
losupramolecular structures means that application of the
otherwise extremely versatile copper-catalysed azide/alkyne
cycloaddition (CuAAC) may be hampered by deleterious reac-
tions20 such as displacement of the original metal by copper
from the catalyst.21 In addition the new triazole units formed
may bind to metals.22
We report here that our self-assembled optically pure, water-
soluble triplex metallohelices8 provide excellent molecular
frameworks on which to perform such late-stage modication.
Through this chemistry we have discovered compounds with
excellent potency against a panel of cancer cell lines, with
enantioselectivity reected in cell cycle studies, plus enhanced
selectivity with respect to a panel of non-cancer cell lines in
vitro. One selected compound displays a remarkable array of
properties: antimetastatic (inhibition of cell migration, re-
adhesion and invasion), cancer stem cell targeting, and colo-
nosphere inhibition competitive with the drug salinomycin.Chem. Sci.
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View Article OnlineMechanistically, the compound does not induce apoptosis but
appears to inhibit Na+/K+ ATPase activity with potency compa-
rable to the drug ouabain.
Results
Click synthesis of new metallohelices
We recently synthesised ranges of optically pure water-soluble
metallohelices in which the ligand strands run in opposing
directions (the “head-to-head-to-tail” or HHT isomers).9 Of
these we selected the system based on [M2L
1
3]
4+ (Fig. 1, R ¼ H)
since it possesses an appealing facially amphipathic architec-
ture. The new metallohelix enantiomers [M2L
2
3]
4+ (M ¼ Zn, Fe)
with perchlorate and chloride counter-ions respectively, syn-
thesised using sub-components 1 and 5-(propargyloxy)picoli-
naldehyde (2), are decorated with three chemically inequivalent
alkyne substituents on one face of the structure.
The 1H NMR spectra have several unusual features that
conrm the topologically asymmetric structure [Fig. 1a]. In
[Zn2L
2
3][ClO4]4 at 293 K, three spectroscopically unique ligand
environments give rise to imine singlets Ha at 9.26, 9.17 and
8.80 ppm. Two of the bpy protons Hb appear in the same region
(9.22 and 9.17 ppm) as a result of intramolecular hydrogen
bonds – see dotted lines in structures of Fig. 1. The third bpy
proton Hb with no such interaction was found at 8.39 ppm.
Similarly, the two sets of ring protons Hd and He arising from
pendant phenyls taking part in bifurcated p-stacks with coor-
dinated bpy units, appear at 6.80 and 5.90 ppm. The third
phenyl group that is insteadp-stacked to a coordinated pyridine
has Hd and He resonances at more conventional chemical shis
of 7.11 and 6.96 ppm. At lower temperatures these signals begin
to broaden, consistent with slowing of phenyl group de-
coordination/rotation (ESI Fig. S3†). The rather rigid arrange-
ment of the ligand strands leads to six distinct resonances for
Hh, clustered at 4.42–4.10 ppm (apparent triplets) and 3.63–
3.47 ppm (approximately doublets of doublets). Three alkyne
proton singlets Hj appear at 3.0–2.8 ppm.
In the same 1H NMR spectrum of Fig. 1 the small singlet at
8.7 ppm is assigned to the HHH isomer of this compound – the
three-fold symmetric compound where all three strands run in
the same direction – and on this assumption we estimate the
selectivity HHT:HHH to be ca. 99%. Other small peaks consis-
tent with the presence of this minor isomer can be seen in the
baseline. At 6.8 ppm a doublet is tentatively assigned to protons
of type e in the HHH isomer. It is interesting to note the absence
of a triplet for type d protons in the region 6.4–6.8 ppm in this
minor component; no such signal is expected since there is no
phenyl-bpy p-stack in the HHH isomer. Similarly, no minor
doublets for type e protons are expected around 6 ppm. As such,
the appearance of these minor isomer peaks corroborates our
assignments for the major isomer.
Reactions employing a range of CuAAC conditions23–25 were
explored and it was found that heating [M2L
2
3]
4+ (M ¼ Zn, Fe)
with benzyl azide in the presence of catalytic copper(I) iodide for
18 h cleanly gave [M2L
3a
3]
4+. The disappearance of the alkyne
resonances in the 1H NMR spectra of [Zn2L
2
3]
4+ at ca. 3 ppm (Hj)
[Fig. 1b] and 78/77 ppm (Cj/Cn) (ESI Fig. S4†) demonstrates thatChem. Sci.the reaction progresses to completion. Upon formation of the
triazole moiety, three new proton singlets (Hk) are evident at ca.
8 ppm and new quaternary carbon resonances (Cl) at ca.
142 ppm are observed. In addition, three new singlets at ca.
5.6 ppm are observed in the 1H NMR spectra of both [Zn2-
L23]
4+and [Fe2L
2
3]
4+ (and 13C at ca. 55 ppm), due to the addition
of the benzyl methylene group (Hm), as well as new resonances
due to the benzyl ring in the aromatic region. The NMR signals
corresponding to the imine, bipyridyl and phenyl units remain
unperturbed by the CuAAC reaction, demonstrating that the
structure of the metallohelix architecture is preserved. The
successful synthesis of all the “clicked” complexes was also
conrmed by high resolution electrospray mass spectrometry
(ESI Fig. S18–23†). For instance, a strong signal was observed by
electrospray mass spectrometry at m/z 464.1580 Da for the tet-
racationic molecular ion of RC,DFe,HHT-[Fe2L
3a
3]Cl4, within
0.001 Da of the calculated value for C105H93Fe2N21O6 (m/z
464.1582 Da). Inductively-Coupled Plasma Mass Spectrometry
(ICP-MS) analysis of the iron triplex metallohelices revealed that
only trace amounts of copper could be detected.
Subsequently fourteen new benzyl triazole-functionalised
metallohelix enantiomers were isolated in a similar manner.
Remarkably, the carboxylic acid derivatives [Fe2L
3e
3]
4+ were
accessible, despite the stability of Fe carboxylates. In all cases,
the triplex architecture was retained, even in the case of
conventionally highly labile Zn(II). Characterizing data
including NMR, MS, circular dichroism (CD), IR and micro-
analysis are detailed in ESI.† NMR and UV-vis experiments
indicate that little decomposition of the product [Fe2L
3a
3]Cl4
occurred over months in aqueous solution (ESI Fig. S14, S15
and S17†).Antiproliferative activity and cell line selectivity studies
The panel of Fe(II) compounds of Fig. 1 were initially evaluated
alongside cisplatin for potency against the human epithelial
colorectal cancer cell line HCT116 p53+/+ (wild-type p53) and
non-cancerous human epithelial retinal pigment cells (ARPE-
19) (Fig. 2).26
The modest potency of parent compound D-[Fe2L
1
3]Cl4
against HCT116 p53+/+ leads to a poor selectivity index: the ratio
of IC50 values of ARPE-19 cells to HCT116 p53
+/+ cells (see Fig. 2
– note log scale). While this is higher for the L enantiomer, the
performance of the alkyne derivatives [Fe2L
2
3]Cl4 is much
improved, with potencies similar to that of cisplatin against
HCT116 p53+/+ but giving rather better selectivity indices. The
“clicked” metallohelices [Fe2L
3a–e
3]Cl4 perform better still. They
are all more potent than cisplatin against the HCT116 p53+/+
colon cancer cells, with the exception of the more moderately
active tricarboxylic acid D-[Fe2L
3e
3]Cl4. These complexes also
exhibit enantioselectivity; in all cases the LFe compounds are
more active than DFe [Fig. 2a]. Pleasingly, the new metal-
lohelices are all signicantly less toxic to non-cancerous ARPE-
19 cells with the DFe enantiomers being substantially less toxic
thanLFe [Fig. 2b]. The resulting selectivity indices show that the
DFe-enantiomers are all more selective than theirLFe analogues;
both D-[Fe2L
3a
3]Cl4, and D-[Fe2L
3c
3]Cl4, have a selectivity indicesThis journal is © The Royal Society of Chemistry 2019
Fig. 1 Metallohelix architectures via asymmetric self-assembly and CuAAC. Synthesis of the new alkyne-appended triplex enantiomers [M2L
2
3]
4+
gives access to a range of optically pure structures of Zn(II) and Fe(II); the stereochemical descriptors for the complexes e.g. RC,DM,HHT refer to
the absolute conﬁgurations at C, the metal, and the directionality of the ligand strands respectively. 1H NMR spectra (500 MHz, CD3CN, 298 K)
show clean conversion of (a) RC-DZn-HHT-[Zn2L
2
3][ClO4]4 to (b) RC-DZn-HHT-[Zn2L
3a
3][ClO4]4. Alkyne resonances j are replaced by triazole
singlets k but otherwise the triplex architecture is unperturbed; *indicates resonances assigned to the HHH isomer.
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View Article Onlinefor these particular cell lines of >30. On the basis that the
former is the simpler compound, it was selected from the click
derivatives for further study.This journal is © The Royal Society of Chemistry 2019Accordingly, the compounds D-[Fe2L
1
3]Cl4, D-[Fe2L
2
3]Cl4 and
D-[Fe2L
3a
3]Cl4 were screened against a larger panel of cell lines
of diﬀerent tissue origins (colon, ovarian, cervical and breastChem. Sci.
Fig. 2 Antiproliferative activity of triplexmetallohelices in cancer andnon-
cancer cells. The half maximum inhibitory concentration (IC50) values are
from triplicatemeasurements using theMTT assay, dosing for 96 h against:
(a) HCT116 p53+/+ colon cancer cells; (b) ARPE-19 (non-cancerous) cells.
The selectivity index (c) i.e. [mean IC50(ARPE-19)]/[mean IC50(HCT116
p53+/+)] for the control drug cisplatin (cisPt), the “parent” triplex [Fe2L
1
3]Cl4,
alkyne triplex [Fe2L
2
3]Cl4 and CuAAC-derived systems [Fe2L
3a–e
3]Cl4.
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View Article Onlinecancers, plus a range of non-cancer). The data are given in Table
1 and the 112 selectivity indices determined (four compounds,
seven cancer cell lines, four non-cancer) are plotted in Fig. 3.Table 1 Cell viability (IC50 mean values, mM) of the investigated compou
Cell line
Compoun
D-[Fe2L
1
3
Cancer cell lines HCT116 p53+/+ (colon) 21.4  1.
HCT116 p53/ (colon) 7.7  3.7
A2780 (ovarian) 6.38  0.
A2780cisR (ovarian) 4.43  0.
HeLa (cervical) 3.8  0.9
MCF-7 (breast) 2.4  0.4
MDA-MB-231 (breast) 7  1
Non-cancer cell lines ARPE-19 (retinal) 31  12b
MRC-5 pd30 (lung) 31  6
HMF (breast) 18  5b
WI-38 (lung) >100b
a The experiments were performed in triplicate or quadruplicate. The cells
stated. The results are expressed as mean values  SD from three or four
Chem. Sci.The metallohelices were without exception more active against
each of the seven cancer cell lines than the four diﬀerent non-
cancer cell lines. Furthermore, they display an over-
whelmingly favourable selectivity compared with the clinically
used chemotherapeutic agent cisplatin. In most instances the
compound D-[Fe2L
3a
3]Cl4 was the most selective.
We noted that while conversion of alkyne D-[Fe2L
2
3]Cl4 to
benzyltriazole D-[Fe2L
3a
3]Cl4 had little eﬀect on potency in the
HCT116 colon cancer cells, potency in the ovarian and breast
cancer cell lines was increased 7 to 25 fold (Table 1). In
contrast, activity against three of the four non-cancer cell lines
was only modestly increased (by <1.3 fold in HMF, 1.5 fold in
ARPE19 and 2 fold in MRC-5 pd30). The click modication
resulted in a 4-fold increase in potency towards the cisplatin-
resistant ovarian cancer cells (A2780cisR) compared to the
cisplatin-sensitive parental cells indicating a lack of cross-
resistance and, unsurprisingly, a distinct mechanism of
action to that of the DNA “alkylator” cisplatin.
The p53 tumour suppressor gene is one of the most
frequently mutated in cancer, commonly causing increased
resistance to chemotherapeutic drugs. While accordingly here
cisplatin was found to be >2 fold less active towards HCT116
p53/ cells than the p53+/+ isogenic clones (Table 1), such
a loss of potency was not observed for any of the D-
metallohelices.Mechanistic studies
We noted that the enantiomer potencies for [Fe2L
2
3]Cl4 (i.e. D >
L) against cancer cells were reversed for [Fe2L
3a
3]Cl4 and the
other click derivatives. We thus compared the eﬀects of the
enantiomer pairs on the cell cycle prole of asynchronously
growing cells. Striking enantiomeric and structure-dependent
diﬀerences were observed (Fig. 4) implying diﬀerent mecha-
nisms of action. Further, since the high selectivity index
compound D-[Fe2L
3a
3]Cl4 did not induce signicant alteration
in the cell cycle prole, the induction of cell death via apoptosis,
a target of many anticancer drug treatments,27–29 was investi-
gated. To our surprise, induction of apoptosis was not observed
via a membrane phosphatidylserine (PS) assay30 for HCT116nds. Cell survival was evaluated using the MTTa assay
d
]Cl4 D-[Fe2L
2
3]Cl4 D-[Fe2L
3a
3]Cl4 Cisplatin
4b 2.9  0.9b 2.2  1.0b 3.3  0.4b
b 3.4  0.2b 3.3  0.3b 7.5  0.7b
1 6.1  0.8 0.9  0.2 3.3  0.2
1 6.1  0.3 0.24  0.02 20  3
16  6 7.6  0.5 14.0  0.9
16  2 2.2  0.2 12.9  0.6
22  1 2.1  0.2 22  2
100  5b 66  7b 6.4  1.0b
65  5 32  5 12  1
14  2b 11  1b 18  2b
>100b 16  3b 2.2  0.8b
were treated with the investigated compounds for 72 h, unless otherwise
independent experiments. b Cells were treated for 96 h.
This journal is © The Royal Society of Chemistry 2019
Fig. 3 Antiproliferative selectivity indices of triplex metallohelices for cancer vs. non-cancer cells. Selectivity index ¼ mean IC50 ratio: (non-
cancer cell line/cancer cell line), IC50 values as listed in Table 1. *Minimum selectivity indices plotted as IC50 (WI-38) > 100 mM.
Fig. 4 Eﬀects of triplex metallohelices on the cell cycle. Analysis by
ﬂow cytometry of propidium iodide-stained cells and quantiﬁcation of
the percentage of the cell population in diﬀerent stages of the cell
cycle for untreated HCT116 p53+/+ cells, and following incubation with
the metallohelices for 24 h (at a concentration of twice the 96 h IC50).
Remarkably the LFe compounds cause accumulation in G2/M phase
while for DFe-L
2 it is G1. The DFe compound of L
3a has little eﬀect.
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View Article Onlinep53+/+ cells except aer prolonged exposure at 2  IC50 (ESI
Fig. S26†).
Time-dependent cellular response proles (TCRPs)
produced by impedance-based monitoring provides predictiveThis journal is © The Royal Society of Chemistry 2019mechanistic information for the action of small molecules.31–33
Ovarian cancer cells (A2780) that have been treated with D-
[Fe2L
1
3]Cl4, D-[Fe2L
2
3]Cl4 and D-[Fe2L
3a
3]Cl4 show clearly
distinct TCRPs (Fig. 5). For the parent metallohelix D-[Fe2L
1
3]Cl4
the initial rise in Cell Index (CI) impedance signal is less
apparent than for other compounds and the period of signal
elevation is the shortest. For the alkyne D-[Fe2L
2
3]Cl4 the CI
signal increases to ca. 1.7 that of the control and the peak is
relatively broad, the signal decreasing steadily over the
measurement period. For the benzyl triazole derivative D-
[Fe2L
3a
3]Cl4 the CI signals reach a much sharper dose-
dependent maximum. A TCRP prole database search31 indi-
cated a similarity with that for compounds that inhibit Na+/K+
stimulated ATPases; a highly conserved integral cell membrane
pump expressed in virtually all cells of higher organisms that
maintains ionic concentration gradients.34 An established
rubidium-based assay35 subsequently showed that D-[Fe2L
3a
3]
Cl4 did indeed inhibit uptake of the cation in A2780 and
HCT116 p53+/+ cell lines under these conditions, by 35–47%
(Fig. 6). This performance is comparable with that of the known
potent Na+/K+-ATPase inhibitor ouabain36 (39–57% inhibition).
In contrast D-[Fe2L
1
3]Cl4 and D-[Fe2L
2
3]Cl4 had little if any
eﬀect.Antimetastatic properties of metallohelices
Colorectal cancer is one of the four most common causes of
cancer deaths,37 and in 90% of instances mortality is ascribed toChem. Sci.
Fig. 5 Time-dependent cellular response proﬁles of A2780 cancer cells treated with increasing concentrations of the metallohelices; cell index
in arbitrary units is a measure of cell sensor impedance: (A) D-[Fe2L
1
3]Cl4 (lines: orange – 4 mM; green – 8 mM; turquoise – 20 mM; blue – 40 mM);
(B) D-[Fe2L
2
3]Cl4 (lines: orange – 2 mM; green – 4 mM; turquoise – 8 mM, blue – 20 mM; magenta – 40 mM); (C) D-[Fe2L
3a
3]Cl4 (lines: orange –
0.125 mM; green – 0.25 mM; turquoise – 0.5 mM; blue – 0.8 mM; dark green – 1.6 mM; magenta – 3.2 mM). The medium containing the tested
compounds was added after 27.5 h of incubation.
Fig. 6 Accumulation of Rb in cells treated with metallohelices. A2780
and HCT116 p53+/+ cells were treatedwith metallohelices and ouabain
(10 mM) for 6 h – the short incubation time was used to secure cell
viability and to mainly detect the upstream eﬀects of the applied drug
– followed by RbCl (5.4 mM) for 3 h. Uptake of Rb+ was determined by
ICP-MS. All results are expressed as the mean  SD from three inde-
pendent experiments. Asterisks indicate a signiﬁcant diﬀerence from
untreated control (100%) with *p < 0.001 calculated by using 2 way
ANOVA.
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View Article Onlinemetastasis, for which there are currently no eﬀective treat-
ments.38,39 Ouabain has been reported to inhibit cancer cell
migration40–43 and to possess antimetastatic activity through its
inhibition of Na+/K+ ATPase.43 On the basis of the mechanistic
discoveries above we investigated the eﬀects ofD-[Fe2L
3a
3]Cl4 on
important steps in the process of metastasis44–46 in the colon
cancer cell line HCT116 p53+/+.
We modelled the detachment of cancer cells from a primary
tumour by an in vitro assay of cell resistance to trypsiniza-
tion.47–49 HCT116 p53+/+ cells grown in monolayer were treated
with the investigated compounds for 3 h and then subjected to
a diluted trypsin solution. The number of cells that resisted the
treatment (i.e. remained attached to the surface) was evaluated
by the sulforhodamine B (SRB) assay. Treatment with D-[Fe2L
1
3]
Cl4 reduced detachment only at higher concentrations [top
panel in Fig. 7] and D-[Fe2L
2
3]Cl4 had no signicant eﬀect. In
contrast, treatment of cells with D-[Fe2L
3a
3]Cl4 signicantly
impeded their detachment.
Re-attachment of cancer cells to tissue at a ‘new’ site in the
body (the site of secondary tumour formation)50 was modelledChem. Sci.in a re-adhesion assay.51,52 Cells were treated with 10 mM
compound for 3 h (a non-toxic dose), detached with trypsin and
re-seeded at a density of 2  104 cells per well. The number of
cells attached aer 30 min incubation was determined by the
SRB assay [middle panel in Fig. 7]. Compounds D-[Fe2L
1
3]Cl4
and D-[Fe2L
3a
3]Cl4 reduced cell re-adhesion by 24% and 58%
respectively.
Cancer cell invasion denes the ability of cells to inltrate
tissue. Using a Matrigel™ transwell assay53,54,70 (see ESI†) it was
shown that while D-[Fe2L
2
3]Cl4 had no eﬀect, D-[Fe2L
1
3]Cl4 and
D-[Fe2L
3a
3]Cl4 reduced HCT116 p53
+/+ invasive ability by 35%
and 58% [bottom panel in Fig. 7].
The overall ability of the compounds to inuence cancer cell
migration and invasion was assessed by wound healing assay
(scratch gap closure)55,72 [Fig. 8a]. While in a control sample
a scratch in a monolayer of HCT116 p53+/+ cells had healed in
24 h to 33%, the presence of non-toxic doses of D-[Fe2L
1
3]Cl4 or
D-[Fe2L
3a
3]Cl4 suppressed healing, leaving 62% and 71%
respectively of the wound open. Cells treated with D-[Fe2L
2
3]Cl4
resembled the control.Cancer stem cell (CSC) targeting
CSCs56 represent a reservoir of resistant and highly aggressive
cancer cells that can remain when the bulk of a tumour has
been eradicated, leading to formation of secondary or tertiary
tumours.57–60 The failure to eliminate or inhibit CSCs is thereby
a major cause of failure of existing anti-cancer treatments61–63
and is a key challenge to improving patient outcomes.64–67
The HCT116 p53+/+ cells68,69 possess a cancer stem cell frac-
tion capable of forming colonospheres from single cells, and
have been utilized in several studies as a CSC model.70–72 The
HCT116 p53+/+ cells were treated with D-[Fe2L
1
3]Cl4 and D-
[Fe2L
3a
3]Cl4 at their respective IC30 concentrations for 72 h, and
subsequently cultured as single cell suspensions in serum-free
media. While both D-[Fe2L
1
3]Cl4 and D-[Fe2L
3a
3]Cl4 were
found to inhibit colonosphere formation in HCT116 p53+/+
under these conditions, D-[Fe2L
3a
3]Cl4 in particular was signif-
icantly more eﬀective than the CSC-selective73–76 drug salino-
mycin (ESI Table S3 and Fig. S27, S28†). Subsequently,
signicant colonosphere inhibition by both D-[Fe2L
1
3]Cl4 andThis journal is © The Royal Society of Chemistry 2019
Fig. 7 In vitro antimetastatic activity of metallohelices (a) eﬀects of the
metallohelices on cancer cell adhesion and resistance to detachment
through use of diluted trypsin enzyme; cells were treated with the
indicated metallohelices at 10 mM and 20 mM respectively for 3 h prior
to addition of trypsin (b) cell re-adhesion assay; cells detached
following trypsinization (and 3 h pre-treatment with themetallohelices
at 10 mM) were assayed for their ability to re-adhere within 30 min, (c)
cell invasion assay; cells were treated with the metallohelices at
equitoxic (2  IC50) concentration for 2 h, followed by assessment of
invasion through Matrigel (see Methods in ESI†).The results are
expressed as the mean  SD from three independent experiments.
Asterisks indicate a signiﬁcant diﬀerence from untreated control
(100%) with *p < 0.05 or **p < 0.001 calculated by using 2 way ANOVA.
Fig. 8 Wound healing assay of metallohelices. (a) Representative
scratch assay images of HCT116 p53+/+ cancer cells and the eﬀect of
treating with metallohelices (at IC50 concentrations) on scratch
closure; images at 0 and 24 h following insertion of a scratch. (b)
Quantiﬁcation of scratch closure at 0, 8.5 and 24 h with cells cultured
in complete media (c) a similar result was obtained in starving medium
conditions [serum-deprived medium (1% BSA)] indicating that the
suppression of wound-healing results at least in part from anti-
migration/invasion rather than being due to cell proliferation resulting
in closure of the scratch.
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View Article OnlineD-[Fe2L
3a
3]Cl4 was also observed in CSC-enriched cells
(HCT116.CD133+). The compounds were equally or slightly
more eﬀective than salinomycin in reduction in the number
and average size of colonospheres [Fig. 9a–f].
Next, we compared the eﬀects of D-[Fe2L
1
3]Cl4, D-[Fe2L
3a
3]Cl4
and salinomycin on HCT116.CD133+ and HCT116.CD133 cells
(Fig. 9 and ESI Fig. S30†) these data indicate that D-[Fe2L
1
3]Cl4
and salinomycin eﬀectively inhibit colonosphere formation
from HCT116.CD133+ cells, but do not signicantly inhibit
colonosphere formation fromHCT116.CD133 cells. This result
can be interpreted to mean that D-[Fe2L
1
3]Cl4 and salinomycin
are CSC-selective agents. On the other hand, D-[Fe2L
3a
3]Cl4 alsoThis journal is © The Royal Society of Chemistry 2019eﬀectively inhibits colonosphere formation from both
HCT116.CD133+ and HCT116.CD133 cells, although being less
eﬀective in CD133 negative cells. The reasonable explanation
of the latter result is that D-[Fe2L
3a
3]Cl4 exhibits a lower selec-
tivity for CSCs than D-[Fe2L
1
3]Cl4 and salinomycin being able to
eﬀectively kill both diﬀerentiated cancer cells and CSCs. As
eﬀective cancer treatments must attack both rapidly-dividing
diﬀerentiated (non-stem) cancer cells and CSCs, D-[Fe2L
3a
3]Cl4
appears to be a promising candidate compound able to over-
come limitations connected with the use of a number of
conventional chemotherapeutics.
The data in Fig. 9g arise from a clonogenic assay that
examines the capability of a single cell to grow into a large
colony through clonal expansion.77 CSC-enriched
HCT116.CD133+ cells incubated for 48 h with 30 mM D-Chem. Sci.
Fig. 9 Growth inhibitory eﬀects in HCT116.CD133+ cancer stem cells. Representative microscopy images of the HCT116.CD133+ colonospheres
in the absence (a) and presence of salinomycin (b), D-[Fe2L
1
3]Cl4 (c), and D-[Fe2L
3a
3]Cl4 (d), treated at their respective IC30 values for 6 days (scale
bar: 100 mm). Quantiﬁcation of colonosphere formation (e and f) under the same conditions. Clonogenic assay on the HCT116.CD133+ (g)
showing the colony forming eﬃciency (i.e. the number of colonies that formed post-drug treatment, with respect to the number of cells seeded)
after treatment with diﬀerent concentrations of salinomycin, (grey circles), D-[Fe2L
1
3]Cl4 (black open circle), and D-[Fe2L
3a
3]Cl4 (black squares)
for 48 h, following growth for 8 days. Data represent the mean value and SD from three independent experiments. p < 0.01, versus control.
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View Article Online[Fe2L
3a
3]Cl4, exhibited no surviving cells aer being allowed to
grow for 8 d; an eﬀect comparable to that of conventional sali-
nomycin. D-[Fe2L
1
3]Cl4 was less eﬀective.
The selective anti-cancer stem cell eﬀects of D-[Fe2L
3a
3]Cl4
were further demonstrated (ESI Table S4†). The IC50 of 1.21 
0.25 mM in CSC-enriched HCT116.CD133+ is around half in
HCT116 p53+/+ under the same conditions; a better diﬀerential
than that observed with salinomycin.
The studies aimed at the mechanism of action of the inves-
tigated metallohelices on CSCs is in progress in our laboratories
and will be published in a separate article. Nevertheless, we
demonstrate in our manuscript that D-[Fe2L
1
3]Cl4 and D-
[Fe2L
3a
3]Cl4 were equally or slightly more eﬀective in killing
CSCs than CSC-selective salinomycin (ESI Fig. S30†). It was
shown recently76 that nucleolin is likely a salinomycin-binding
target and a critical regulator involved in human neuroblas-
toma CSC activity. It is, therefore, possible, due to the similar
eﬀectivity of the investigated metallohelices (D-[Fe2L
1
3]Cl4 and
D-[Fe2L
3a
3]Cl4) and salinomycin to kill HCT116.CD133
+ CSCs,
that their binding to nucleolin may also be responsible for the
anticancer and anti-CSC like cell activities of D-[Fe2L
1
3]Cl4 and
D-[Fe2L
3a
3]Cl4.
Conclusions
One of the key advantages of our metallohelix assemblies is
their great stability with respect to dissociation or hydrolysis.
This sort of stability will be necessary in order for any such
compound to nd its way into clinical use, and has here allowed
the use of an extremely eﬃcient CuAAC post-assembly modi-
cation of the triplex alkynyl enantiomers [M2L
2
3]. This reactionChem. Sci.gave rapid access to a new range of functionalised compounds
and led to the discovery of D-[Fe2L
3a
3]Cl4; a compound with an
unusual combination of pharmacological properties.
In a study involving an unusually wide range of cancer and
non-cancer cell types, the new “clicked” compounds demon-
strated enhanced potency. More importantly however the
selectivity for cancerous over non-cancerous cells was greatly
improved; this bodes well for the development of compound
with a wider therapeutic window than conventional chemo-
therapeutic agents such as cisplatin. Further, in contrast to
observations for conventional drugs,78 a p53 mutated cell line
did not show resistance to the compound.
While some part of the observed selectivity of D-[Fe2L
3a
3]
4+
probably arises from electrostatic targeting of the anionic outer
leaet of cancer cells (as is proposed for cationic anticancer
peptides79–82) the enantiomer eﬀects observed here point to
greater subtlety. The D compound is much more selective than
L for cancer cells, and this is reected in a remarkable diﬀer-
ence in cell cycle arrest observations. It was also discovered that
D-[Fe2L
3a
3]Cl4 inhibits Na
+/K+ ATPase activity with potency
comparable to that of the conventional inhibitor ouabain.
These mechanistic observations led to the discovery of
a remarkable array of properties of D-[Fe2L
3a
3]Cl4 alongside its
high potency and selectivity. The compound suppresses key
metastatic capacities of cancer cells, reducing their ability to
detach from other cells, migrate, invade and re-adhere else-
where. Compound D-[Fe2L
3a
3]Cl4 exhibits selective toxicity for
colon cancer stem cell-enriched cell populations, challenging
some of the most selective compounds of any kind identied to
date. Additionally, D-[Fe2L
3a
3]Cl4 inhibits the formation of
colonospheres by specically targeting CD133-positive, CSC-likeThis journal is © The Royal Society of Chemistry 2019
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View Article Onlinecells. Thus D-[Fe2L
3a
3]Cl4 is identied as a potential lead
compound for investigation as a selective anti-cancer, anti-
metastatic and CSC-targeting drug.
More generally, while the precise molecular basis for the
diﬀerence between the benzyltriazolyl-clicked compounds and
the parent enantiomers is not known, it is clear that these
discoveries would be much harder to unearth without access to
post-assembly modication. Further, we now know that metal-
lohelices, like conventional medicinal compounds, respond to
chemical modication in such a manner as to facilitate opti-
mization of biological and physicochemical properties.
Experimental
Full details of synthesis, characterization and anti-cancer
experiments are provided in the electronic ESI.† Outlines of
key procedures are detailed in the following.
Synthesis of water-soluble alkyne-functionalised triplex
metallohelices
Anhydrous iron(II) chloride (2 equiv.) was added to a stirred
solution of the desired chiral amine, 2-([2,20-bipyridin]-5-
ylmethoxy)-1-phenylethan-1-amine (3 equiv.) and 5-(prop-2-yn-
1-yloxy)picolinaldehyde (3 equiv.) in methanol (20 ml) at
ambient temperature to give a purple solution that was then
heated to reux (85 C) for 48 h. Themixture was allowed to cool
to ambient temperature, ltered through a Celite plug, and the
solvents were removed in vacuo to give HHT-[Fe2L
2
3]Cl4 as
a dark purple solid (>95% yield).
Post-assembly modication of triplex metallohelices
HHT-[Fe2L
2
3]Cl4 (1 equiv.) and the chosen benzyl azide (4.5
equiv.) were dissolved in methanol (10 ml) in the presence of
copper(I) iodide (0.1 equiv.). The reaction mixture was heated at
65 C for 18 h under inert argon atmosphere. Aer cooling to
ambient temperature, the suspension was ltered to remove
copper salts and the purple product HHT-[Fe2L
3
3]Cl4 was iso-
lated by the addition of ethyl acetate. NMR, infrared and high-
resolution mass spectrometric data were consistent with the
proposed formulations. CD spectra of enantiomers in methanol
were equal and opposite.
Antiproliferative activity (MTT assay)
The human ovarian carcinoma cisplatin-sensitive A2780 cells,
cisplatin-resistant A2780cisR (a cisplatin-resistant variant of
A2780 cells), human cervical carcinoma HeLa cells, human
breast cancer MCF-7 cells and human colorectal carcinoma cells
HCT-116 (for experiments performed at the Czech Academy of
Sciences) were kindly supplied by Professor B. Keppler,
University of Vienna (Austria). Human colon carcinoma cells
expressing p53 (HCT116 p53+/+) were a kind gi of Dr M.
Brazdova, Institute of Biophysics, Brno (Czech Republic). Highly
invasive breast carcinoma MDA-MB-231 cells and human MRC-
5 pd30 cells derived from normal lung tissue were purchased
from the European collection of authenticated cell cultures
(ECACC) (Salisbury, UK). Isogenic clones of p53+/+ and p53/This journal is © The Royal Society of Chemistry 2019HCT116 colon carcinoma cells for experiments performed at the
University of Hudderseld were a kind gi from Bert Vogelstein
(Johns Hopkins University, Maryland, USA). ARPE19 and WI38
cells were both purchased from ATCC (American Type Culture
Collection) and HMF cells were purchased from ScienCell
Research Laboratories, Inc.
Cells were incubated in 96-well plates in complete cell
medium, containing DMEM supplemented with 10% fetal calf
serum and L-glutamine (2 mM). Plates were incubated for 24 h
at 37 C in an atmosphere of 5% CO2, before drug exposure,
then incubated for 96 h with drug. A volume of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
solution (0.5 mgml1) was added to each well and incubated for
a further 4 h. These solutions were removed, dimethyl sulfoxide
was added to each well, and the absorbance at 540 nm was read
using a Thermo Scientic Multiskan EXmicroplate photometer.
The IC50 values were determined from a plot of percentage cell
survival against drug concentration (in mM). All assays were
conducted in triplicate and the mean IC50  standard deviation
was determined.
Cell cycle assay
PBS (300 mL) containing propidium iodide (50 mg ml1) and
RNAse A (80 mg ml1) was added to drug-treated cells before
incubation for 30 min and FACS analysis. The assay was
repeated four times with each compound and the mean
percentage of cells in each phase  standard deviation was
determined. Red uorescence was observed at 488 nm excita-
tion by ow cytometry and data were analysed using Flowjo V10.
Time-dependent cellular response proling
The impedance monitoring of cell growth was performed using
an xCELLigence RTCA SP Real-time cell analyser. Cells were
added and grown for 22–28 h, before tested compounds were
added to themedium at varying concentrations. The impedance
was measured for an additional 80 h.
Rubidium-based assay
Cells were seeded in 6-well plates and incubated for 24 h at
37 C in an atmosphere of 5% CO2. Cells were then incubated
with drug for 6 h, and subsequently the medium was removed
and cells were washed with PBS. Cells were then incubated with
RbCl (5.4 mM) for 3 h, washed and counted. Rubidium content
was determined by ICP-MS.
Wound healing assay
Cells were seeded in 12-well plates and incubated in complete
medium (10% FBS/DMEM/gentamycin) at 37 C in an atmo-
sphere of 5% CO2. The medium was removed and the bottom of
the well was scratched with a 10 mL pipette tip (550–650 mm
gaps). Wells were washed to remove detached cells before drug
was added, dissolved in complete or starving medium, and
plates were incubated for 24 h. Images were taken at several
time intervals post scratching, and automated analysis was
performed using TScratch soware (MATLAB).Chem. Sci.
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View Article OnlineInhibition of colonosphere formation
Cells were treated with drug (IC30 concentration) for 72 h,
washed, harvested with StemPro Accutase, and plated in ultra-
low attachment 96-well culture plates (300 cells per well).
Cells were cultured in for 6 days without disturbing the plates or
replenishing the medium and the number/size of spheres were
determined using an inverted microscope.
Clonogenic assays
Cells were seeded in ultra-low attachment 6-well plates and
cultured for 4 days, to allow pre-spheroid formation. Cells were
treated with drug for 48 h, and dissociated into single cell
suspensions using StemPro Accutase. Single cells were seeded
in normal 6-well plates (3000 cells per well) and cultured for 8
days. Methylene blue solution (1% in water : methanol 1 : 1)
was added for 30 min to stain the formed colonies, excess was
washed out, and colonies containing >50 cells were counted.
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